AMLX
Closed
Amylyx Pharmaceuticals Inc
6.41
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 6.41
Day's Range: 6.185 - 6.52
Send
sign up or login to leave a comment!
When Written:
29.34
Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that is focused on developing therapies for neurodegenerative diseases. The company was founded in 2013 by Joshua Cohen, Justin Klee, and Justin Yang. Amylyx is headquartered in Cambridge, Massachusetts.
The company's lead drug candidate is AMX0035, a combination of two small molecules that has shown promising results in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. AMX0035 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a Phase 3 clinical trial.
Amylyx has also developed a drug discovery platform called the Amylyx Platform, which is designed to identify and develop new therapies for neurodegenerative diseases. The platform uses a combination of computational and experimental approaches to identify potential drug targets and develop new drug candidates.
In addition to ALS, Amylyx is also exploring the potential of its drug discovery platform in other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. The company has raised over $100 million in funding from investors including Morningside Ventures, Samsara BioCapital, and the ALS Investment Fund.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's lead drug candidate is AMX0035, a combination of two small molecules that has shown promising results in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. AMX0035 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) and is currently being evaluated in a Phase 3 clinical trial.
Amylyx has also developed a drug discovery platform called the Amylyx Platform, which is designed to identify and develop new therapies for neurodegenerative diseases. The platform uses a combination of computational and experimental approaches to identify potential drug targets and develop new drug candidates.
In addition to ALS, Amylyx is also exploring the potential of its drug discovery platform in other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. The company has raised over $100 million in funding from investors including Morningside Ventures, Samsara BioCapital, and the ALS Investment Fund.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!